Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer.
about
Epithelial membrane protein-1 is a biomarker of gefitinib resistance.EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinibTen things you should know about protein kinases: IUPHAR Review 14Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor SensitivityAZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancerErbB polymorphisms: insights and implications for response to targeted cancer therapeuticsThe BRAF oncoprotein functions through the transcriptional repressor MAFG to mediate the CpG Island Methylator phenotypeOptimization of substituted 6-salicyl-4-anilinoquinazoline derivatives as dual EGFR/HER2 tyrosine kinase inhibitorsMET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC CellsThe histone H3K9 demethylase KDM3A promotes anoikis by transcriptionally activating pro-apoptotic genes BNIP3 and BNIP3LBivalent inhibitors of the tyrosine kinases ABL and SRC: determinants of potency and selectivityStructure-based ensemble-QSAR model: a novel approach to the study of the EGFR tyrosine kinase and its inhibitors.Comprehensive structural and functional characterization of the human kinome by protein structure modeling and ligand virtual screening.Protein kinase inhibitor-induced endothelial cell cytotoxicity and its prediction based on calculated molecular descriptors.Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells.Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors.A novel humanized mouse lacking murine P450 oxidoreductase for studying human drug metabolism.Probing the probes: fitness factors for small molecule tools.Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidenceThe epidermal growth factor receptor inhibitor gefitinib prevents the progression of pancreatic lesions to carcinoma in a conditional LSL-KrasG12D/+ transgenic mouse model.Tyrosine kinases as targets in cancer therapy - successes and failures.Structure-guided optimization of small molecule c-Abl activatorsAdvances in molecular therapies in patients with brain tumors.Developing inhibitors of the epidermal growth factor receptor for cancer treatment.Butein, a novel dual inhibitor of MET and EGFR, overcomes gefitinib-resistant lung cancer growth.Monitoring Conformational Changes in the Receptor Tyrosine Kinase EGFR.The discovery of novel protein kinase inhibitors by using fragment-based high-throughput x-ray crystallography.Assays for membrane tyrosine kinase receptors: methods for high-throughput screening and utility for diagnostics.Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer.Resveratrol overcomes gefitinib resistance by increasing the intracellular gefitinib concentration and triggering apoptosis, autophagy and senescence in PC9/G NSCLC cellsA review of erlotinib and its clinical use.Control of FLIP(L) expression and TRAIL resistance by the extracellular signal-regulated kinase1/2 pathway in breast epithelial cells.HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo.The Chicago Thoracic Oncology Database Consortium: A Multisite Database Initiative.A useful EGFR-TK ligand for tumor diagnosis with SPECT: development of radioiodinated 6-(3-morpholinopropoxy)-7-ethoxy-4-(3'-iodophenoxy)quinazolineIdentification of quinazoline compounds as novel potent inhibitors of Wnt/β-catenin signaling in colorectal cancer cells.Famitinib exerted powerful antitumor activity in human gastric cancer cells and xenografts.HER-2-directed, small-molecule antagonistsProtein kinase inhibitors: contributions from structure to clinical compounds.Epidermal growth factor receptor-regulated miR-125a-5p--a metastatic inhibitor of lung cancer.
P2860
Q24535592-03A98FE4-A79F-452E-8225-834712EA9AF3Q24561953-4E046992-CD14-4DF4-8D16-0C7E4ED20B60Q26849417-411C10FE-1F01-44F4-AC36-0EDC1844C9DCQ27644014-956DCD0C-B7EB-49E6-9DB8-C88D5F4B0005Q27853013-6136865F-B3FC-4C4D-A173-E0745BA7286EQ28084565-21E554BE-6CEA-4F0C-B54C-B95A9213F377Q28247866-4408D440-A008-4A52-8231-65566C42C2F9Q28535038-706BE497-B468-4C15-95FB-685C89EBA782Q28551045-D00890FA-5927-429C-B73C-261C73CF8CCAQ28829578-EE0E7A63-A93D-43EC-BE98-AF1A99FB35B4Q30155965-10D79E08-850C-474E-8989-BF65ED6C4351Q30356771-A9C02300-779A-49EF-9FC2-A17A3681821EQ30393891-9518A373-48E8-42A1-A834-616663D8004AQ33466404-E01386AA-7256-47D7-AF0C-5247A9A0B7CCQ33533700-74035706-CB02-4A88-BA09-D6304BFF0106Q33635861-DF4F90D2-80B4-479A-9A14-1B630732FC71Q33849042-299A0229-A892-4E74-BB59-CB856B4656AFQ34001269-C76DE8A8-AF08-4864-803E-ACFCA221D6AEQ34011705-75266333-2E43-424F-99ED-09615BE028A7Q34681112-3F28E4F9-A25B-4A65-8D51-B6FBF78A25AEQ35095147-8C6F704E-762E-479C-BEA6-389A078E7A9FQ35103542-2E44B7B0-95F2-4A28-85C7-17E4926217B1Q35113656-23B75930-B5B9-43C2-8CCD-E0B0E16844D0Q35157038-83C5D207-13B7-4307-B0D2-69ACDCD2B260Q35196999-9281C2D4-96BB-4710-A98B-4DED4E5F9FF6Q35962944-E375B3D6-D891-4114-B504-D2B33A4771E4Q36033077-96B2EB12-387B-4DF2-8504-8DAD99C41DDCQ36192716-5168D438-D29F-4449-8B31-5F0400D7FB87Q36302860-48115EC3-6DDE-40C1-881D-AD6CBA6E1D9AQ36346111-63206012-BB26-4314-9B6A-666B81E7E5EFQ36376408-CC308E84-6957-4486-A74B-938C252AF94EQ36418691-4245B207-6003-4816-AC8B-BDA77FC788AAQ36729440-A160CB57-274E-4344-AFE3-8CC99A990496Q36803187-B95A357F-C7DC-42F9-B5EC-7AF7AF40A95AQ36902441-B74BBBDE-FC01-40C2-838A-10950355A431Q36998222-AE2C0851-F094-45E8-A418-BA960A3832CAQ37204806-99647D34-041B-4D72-9A4F-31E8A13290D8Q37336019-FC6C3586-0CE1-4C3E-92FD-9CE84D0AD115Q37417742-BAF3A13E-5880-45FC-8836-6753002B990BQ37420152-14F2901F-99FC-45D0-A0CF-C9AC8C4239A7
P2860
Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Studies leading to the identif ...... ed to the treatment of cancer.
@en
Studies leading to the identif ...... ed to the treatment of cancer.
@nl
type
label
Studies leading to the identif ...... ed to the treatment of cancer.
@en
Studies leading to the identif ...... ed to the treatment of cancer.
@nl
prefLabel
Studies leading to the identif ...... ed to the treatment of cancer.
@en
Studies leading to the identif ...... ed to the treatment of cancer.
@nl
P2093
P1476
Studies leading to the identif ...... ed to the treatment of cancer.
@en
P2093
A A Godfrey
A J Barker
J J Barlow
J R Woodburn
K H Gibson
L Henthorn
L Richards
L Scarlett
P304
P356
10.1016/S0960-894X(01)00344-4
P407
P577
2001-07-01T00:00:00Z